Pinpoint Genomics | GenomeWeb

Pinpoint Genomics

In marketing its newly launched Pervenio lung cancer prognostic test, Life Technologies' sales force is targeting specialist thoracic surgeons and medical oncologists in 48 US states.

Life Technologies this week launched Pervenio Lung RS – a quantitative PCR-based assay for lung cancer prognosis that gauges the expression of 14 genes – through its CLIA lab in Sacramento, Calif.

This story has been updated from a previous version to include additional information about the QuantStudio Dx platform.

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

NEW YORK (GenomeWeb News) – Life Technologies said today that it has acquired Pinpoint Genomics and its early-stage non-small cell lung cancer test designed to help doctors identify early-stage patients at high risk for progression to late-stage disease.

By Tony Fong
NEW YORK (GenomeWeb News) – Genetic test maker Pinpoint Genomics has moved into commercialization phase with the launch of its first product, a prognostic test for non-small cell lung cancer.

Roche said this week that its Cobas CT/NG test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.